Sivelestat

DRUG4 trials

Sponsors

Eli Lilly and Company, Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Assistance Publique - Hôpitaux de Paris

Conditions

Acute Lung InjuryAortic DissectionCardiac DiseaseCardiovascular Diseases (CVD)Respiratory Distress Syndrome, AdultSepsisSystemic Inflammatory Response Syndrome

Phase 1

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

CompletedNCT00036062

Eli Lilly and CompanyAcute Lung Injury, Respiratory Distress Syndrome, Adult

Start: 2001-08-31End: 2002-12-31Target: 600Updated: 2006-07-19

Phase 2

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not yet recruitingNCT06381661

Assistance Publique - Hôpitaux de ParisSepsis

Start: 2026-05-01End: 2031-05-01Target: 2000Updated: 2026-01-27

Phase 3

Efficacy and Safety of Sivelestat in Preventing Postoperative Acute Lung Injury or Acute Respiratory Distress Syndrome After Cardiac Surgery

CompletedNCT06276569

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolCardiac Disease

Start: 2024-02-18End: 2025-07-30Updated: 2025-08-06

Unknown Phase

Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)

RecruitingNCT06195267

Nanjing Medical UniversityAortic Dissection, Cardiovascular Diseases (CVD), Systemic Inflammatory Response Syndrome

Start: 2024-07-01End: 2025-12-31Target: 500Updated: 2024-11-22